Since the introduction of targeted therapeutics in the late 1990s, the drug development pipeline has expanded to include thousands of small molecules and biologics. More than a thousand oncology agents are evaluated in >40,000 clinical trials, to add to the millions of publications already available.
Dynamic changes in the clinical and competitive landscape provide a significant challenge to successfull drug development and optimal patient care. BLU Ampersand creates the tools that bring current and relevant information together in one place – so you can plan for success.
Our company merges scientific expertise, innovative information technology, and strategic thinking; this unique blend of skills is well represented by the & (am-per-sand: noun, 1. a character or symbol for and).
